Solid Biosciences Inc. — Director's Dealing 2018

Feb 2, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Solid Biosciences Inc. (SLDB)
CIK: 0001707502
Period of Report: 2018-01-30

Reporting Person: Koppel Adam (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-01-25	Common Stock	M	1689444	—	Acquired	1689444	Indirect
2018-01-30	Common Stock	P	300000	$16.00	Acquired	1989444	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-10-26	LLC Units	$	A	1223240	Acquired		Common Stock (1037919)	Indirect
2018-01-25	LLC Units	$	M	1991097	Disposed		Common Stock (1689444)	Indirect

Footnotes

F1: Represents shares held directly by BCLS SB Investco, LP ("BCLS").

F2: The governance, investment strategy and decision-making process with respect to investments held by BCLS is directed by Bain Capital Life Sciences Investors, LLC, whose managers are Jeffrey Schwartz and Adam Koppel. By virtue of the relationships described in these footnotes, Dr. Koppel may be deemed to share voting and dispositive power with respect to all of the shares of Common Stock held by BCLS. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

F3: In connection with the Issuer's initial public offering, immediately prior to the effectiveness of the Issuer's Registration Statement on Form S-1 relating thereto, the Issuer, which was previously organized as a limited liability company, converted to a corporation (the "Corporate Conversion"). Prior to the Corporate Conversion, BCLS held 1,991,097 LLC Units of the Issuer, including 112,770 Series C Common Units acquired for a total purchase price of $1,249,999.07 and 1,110,470 Series 2 Preferred Units acquired for a total purchase price of $ 12,500,560.97, in each case on October 26, 2017. In connection with the Corporate Conversion, all outstanding units of the Issuer were converted into shares of Common Stock on a one-for-0.8485 basis in an exempt transaction pursuant to Rule 16b-7. As a result, following the Corporate Conversion, BCLS held 1,689,444 shares of Common Stock.

F4: Represents shares purchased in the Issuer's initial public offering.